Understanding Degenerative Myelopathy
Degenerative myelopathy (DM) is a progressive neurological disorder that affects dogs, leading to a non-painful hind limb paralysis and, ultimately, a loss of mobility. This devastating disease often results in dogs being humanely euthanized within six to twelve months after the onset of clinical signs due to the debilitating effects on their quality of life.
Definition and Overview
Degenerative myelopathy is characterized by the gradual deterioration of the spinal cord, specifically the white matter responsible for transmitting signals between the brain and the limbs. The disease primarily affects the hind limbs and progresses slowly over time. Initially, dogs may experience weakness and loss of coordination in their hind limbs, which gradually worsens as the disease advances. It’s important to note that DM is not a painful condition.
Genetic Basis
Degenerative myelopathy is associated with a genetic abnormality in dogs. The most common form of the disease is caused by a genetic mutation in a gene coding for superoxide dismutase 1 (SOD1). This mutation affects the normal functioning of the protein, leading to the degeneration of the spinal cord. Certain breeds, such as German Shepherds, German Shepherd crosses, Siberian Huskies, and Collies, are more susceptible to developing DM due to these genetic factors (VCA Hospitals).
Genetic testing is available to identify dogs at risk of degenerative myelopathy. This testing categorizes dogs into three groups: “clear,” “carriers,” or “at risk.” Dogs classified as “clear” do not carry the mutated gene, while “carriers” have one copy of the gene but do not typically develop the disease. Dogs classified as “at risk” have two copies of the mutated gene and are more likely to develop degenerative myelopathy.
Understanding the definition and genetic basis of degenerative myelopathy is crucial for dog owners to recognize the signs and take appropriate steps to manage the disease. In the next sections, we will explore the symptoms, progression, breeds at risk, diagnosis, management, and potential treatments for degenerative myelopathy in dogs.
- Incredible Value: Give your pup the gut health and allergy support they deserve while enjoying our best-selling chews at an incredible value with this exclusive 2-pack
- America's #1 Selling Probiotic for Dogs: PetLab Co.’s premium quality dog probiotics were the top-selling dog health supplement on Amazon in 2022. And owners across America are loving the benefits
- Support for Paw Licking, Itchy Skin & Healthy Yeast Levels: Each tasty probiotic chew is formulated with prebiotics and probiotics. Including 8 strains of beneficial bacteria to support the immune system and dog’s seasonal allergies
- Digestive Health: This probiotic supplement also contains Inulin (a prebiotic for dogs) and Pumpkin for dogs to support digestive health and help counter occasional diarrhea and constipation
- Manufactured in the USA & NASC Certified: Our mission is to ensure the very best quality through research and rigorous production practices. All our dog health supplies are manufactured in the USA using ingredients sourced from prime locations in the US & worldwide
Symptoms and Progression
Degenerative myelopathy in dogs is a progressive neurodegenerative condition that primarily affects the spinal cord. Understanding the clinical signs and disease progression is crucial for early detection and management.
Clinical Signs
The clinical signs of degenerative myelopathy often begin with subtle weaknesses in one hind limb, gradually progressing to involve both hind limbs over time. The initial symptoms may include:
- Difficulty rising
- Hind limb weakness
- Incoordination
- Muscle loss
- Scuffed toenails on hind limbs (Cornell University College of Veterinary Medicine)
As the disease progresses, dogs may experience a loss of coordination and balance, leading to an ataxic walk. The hind limbs become progressively weaker, and muscle wasting becomes more apparent. It’s important to note that degenerative myelopathy typically does not affect bladder and bowel control in the early stages (VCA Hospitals).
Disease Progression
Degenerative myelopathy is a progressive and incurable disease in dogs. The disease tends to progress rapidly, with most dogs becoming paraplegic within six months to a year after the onset of clinical signs. The timeline and severity of progression can vary among individual dogs.
As the spinal cord continues to degenerate, the dog’s mobility becomes severely restricted. The hind limb weakness worsens, eventually leading to an inability to walk. Bladder and bowel control may also become more difficult to maintain as the disease advances.
While degenerative myelopathy is irreversible, supportive care and management strategies can help improve the dog’s quality of life and slow down the progression of the disease. It’s important to work closely with a veterinarian to develop a tailored treatment plan based on the individual needs of the affected dog. For more information on treatment options, refer to our article on treatment for degenerative myelopathy in dogs.
Understanding the clinical signs and progression of degenerative myelopathy is essential for early identification and intervention. If you notice any of the mentioned symptoms in your dog, it is crucial to consult with a veterinarian for proper diagnosis and guidance on managing the condition.
Breeds at Risk
Degenerative myelopathy (DM) was previously considered a disease primarily affecting German Shepherds. However, it has since been identified in many other breeds as well. Some of the commonly affected breeds, in addition to German Shepherds, include Boxers, Pembroke and Cardigan Welsh Corgis, and Golden Retrievers. While DM is more prevalent in these breeds, it is important to note that any dog breed can be susceptible to this condition.
It is crucial for dog owners to be aware of the potential risk of DM in their breed. Genetic testing is available to identify dogs at risk of developing degenerative myelopathy. This testing categorizes dogs into three groups based on their genetic status: ‘clear’, ‘carriers’, or ‘at risk’ (Fitzpatrick Referrals). Identifying the genetic status of a dog can provide valuable information for breeders and owners, allowing them to make informed decisions regarding breeding programs and potential health concerns.
The presence of a specific genetic mutation, known as SOD-1, has been identified as a major risk factor for degenerative myelopathy in dogs (VCA Hospitals). Dogs that inherit one or two copies of this gene have an increased risk of developing DM. However, it is important to note that not all dogs carrying these genes will develop the condition. Other genetic and environmental factors are believed to contribute to the development of DM.
To determine the genetic status of a dog, DNA testing can be performed through organizations like the Orthopedic Foundation for Animals. This testing helps identify the presence of the SOD-1 mutation, providing valuable information about the dog’s risk of developing degenerative myelopathy (VCA Hospitals). It is important to work closely with veterinarians and genetic testing laboratories to understand the implications of these results and develop appropriate management strategies.
Understanding the breeds at risk for degenerative myelopathy and utilizing genetic testing can assist in proactive management and informed decision-making for dog owners and breeders. By being aware of the potential risk, steps can be taken to provide appropriate care and support for dogs at risk of developing this condition. For more information on the symptoms, diagnosis, and treatment options for degenerative myelopathy in dogs, refer to our article on treatment for degenerative myelopathy in dogs.
Diagnosis and Management
When it comes to diagnosing and managing degenerative myelopathy in dogs, early detection and appropriate care are crucial. Let’s explore the diagnostic procedures used to identify the condition and the available treatment options for affected dogs.
Diagnostic Procedures
To diagnose degenerative myelopathy (DM) in dogs, veterinarians employ various diagnostic procedures. These can include a thorough physical examination, neurological evaluation, and advanced imaging techniques such as MRI or CT scans. However, the definitive diagnosis of DM is often made through DNA testing. The Orthopedic Foundation for Animals offers a DNA test to identify the SOD-1 mutation, which is associated with an increased risk of developing degenerative myelopathy. It’s important to note that not all dogs carrying the SOD-1 mutation will develop DM, as other genetic and environmental factors may play a role.
Treatment Options
Unfortunately, there is currently no cure for degenerative myelopathy in dogs. The progressive nature of the disease means that affected dogs will gradually lose mobility and may eventually become incontinent (Veterinary Referral Associates). However, there are some management strategies that can help improve the quality of life for dogs with DM.
Palliative care is often recommended for dogs once mobility has been compromised. This includes providing a supportive environment and assisting the dog with a doggie wheelchair or mobility cart to maintain mobility for as long as possible. It’s important to keep the dog at a healthy weight, as obesity can add extra strain to the body (Veterinary Referral Associates).
While there is no specific medication to halt or reverse the progression of DM, some pet owners have reported slowing the progression of the disease with a combination of supplements and medications. These may include vitamins B, C, and E, epsilon-aminocaproic acid, N-acetylcysteine, and prednisone. However, it’s essential to consult with a veterinarian before starting any treatment regimen for degenerative myelopathy.
In addition to medical management, providing a safe and supportive environment for the dog is crucial. This may involve making modifications to the home, such as using non-slip mats on slippery surfaces and creating ramps or steps to assist with mobility.
Understanding the diagnosis and management options for degenerative myelopathy can help dog owners provide the best possible care for their furry companions. While the disease is progressive and incurable, early detection, supportive care, and the guidance of a veterinarian can help improve the dog’s quality of life as they navigate this challenging condition.
Research and Potential Treatments
Researchers and veterinarians are actively studying degenerative myelopathy (DM) in dogs to better understand the disease and explore potential treatment options. Here, we discuss recent studies and future prospects in the field of DM research.
Recent Studies
One promising area of research focuses on the drug riluzole, which was the first FDA-approved medication to treat ALS in humans in 1995. Riluzole works by preventing the build-up of excitatory nerve signaling molecules that can kill nerve cells in affected dogs and humans (AKC Canine Health Foundation).
A study on riluzole for DM aims to evaluate its safety and efficacy in dogs. This research also aims to show the utility of a recently discovered biomarker to track the clinical progression of DM in dogs. The long-term goal is to study multiple treatment options simultaneously at various institutions in the United States, with the ultimate aim of developing effective treatments for DM (AKC Canine Health Foundation).
Dr. Joan Coates, the Principal Investigator of the riluzole study, is working with colleagues at various universities through Project DM. This collaboration allows for the collection of reliable data at multiple veterinary hospitals, enabling more dogs and their owners to participate in clinical trials. By working together, they aim to accelerate progress in developing treatments for DM.
Future Prospects
The identification of a genetic mutation and gene modifiers that increase the risk of developing DM in certain dog breeds has been a significant advancement. Researchers, with funding from previous grants, have described the structural changes in the nervous system that define DM and studied a molecule that can be measured in the fluid surrounding the central nervous system to monitor disease progression.
While there is currently no cure for DM, ongoing research provides hope for the future. By continuing to study the genetic basis of the disease and exploring potential treatment options, researchers aim to improve the understanding and management of DM in dogs. It is through these efforts that we may one day develop effective therapies to slow the progression of this devastating disease.
For dog owners seeking more information on managing DM and available treatment options, please refer to our article on treatment for degenerative myelopathy in dogs. Stay informed and consult with your veterinarian for the most up-to-date guidance on managing your dog’s condition.
